Time- and temperature-dependent stability of growth factor peptides in human autologous serum eye drops

Cornea

Volumn 28, Issue 2, 2009, Pages 200-205

  Bradley, Jay C ^a   Simoni, Jan ^b   Bradley, Rachael H ^a   McCartney, David L ^b   Brown, Sandra M ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^c Cabarrus Eye Center   (United States)

Author keywords

Autologous serum; Growth factor peptides; Neurotrophic keratopathy

Indexed keywords

AUTOLOGOUS SERUM EYE DROP; CALCITONIN GENE RELATED PEPTIDE; ENDOTOXIN; EPIDERMAL GROWTH FACTOR; EYE DROPS; NERVE GROWTH FACTOR; SOMATOMEDIN C; SUBSTANCE P; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ARTICLE; DRUG MANUFACTURE; HUMAN; HUMAN EXPERIMENT; LIPID PEROXIDATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STABILITY; SERUM; STORAGE; STORAGE TEMPERATURE; TEMPERATURE DEPENDENCE; TIME;

ADULT; DRUG STABILITY; DRUG STORAGE; ENDOTOXINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPID PEROXIDATION; MALE; OPHTHALMIC SOLUTIONS; OSMOLAR CONCENTRATION; PILOT PROJECTS; SERUM; TEMPERATURE; TIME FACTORS;

EID: 67650644562     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e318186321e     Document Type: Article

References (14)

1. Garcia-Hirschfeld J, Lopez-Briones LG, Belmonte C. Neurotrophic influences on corneal epithelial cells. Exp Eye Res. 1994;59:597-605.
2. Nakamura T, Inatomi T, Sotozono C, et al. Transplantation of autologous serum-derived cultivated corneal epithelial equivalents for the treatment of severe ocular surface disease. Ophthalmology. 2006;113:1765-1772.
3. Matsumoto Y, Dogru M, Goto E, et al. Autologous serum application in the treatment of neurotrophic keratopathy. Ophthalmology. 2004;111: 1115-1120.
4. Bonini S, Lambiase A, Rama P, et al. Topical treatment with nerve growth factor for neurotrophic keratitis. Ophthalmology. 2000;107:1347-1351; discussion 1351-1352.
5. Imanishi J, Kamiyama K, Iguchi I, et al. Growth factors: importance in wound healing and maintenance of transparency of the cornea. Prog Retin Eye Res. 2000;19:113-129.
6. Klenkler B, Sheardown H. Growth factors in the anterior segment: role in tissue maintenance, wound healing and ocular pathology. Exp Eye Res. 2004;79:677-688.
7. Geerling G, MacLennan S, Hartwig D. Autologous serum eye drops for ocular surface disorders. Br J Ophthalmol. 2004;88:1467-1474.
8. Lagnado R, King AJ, Donald F, et al. A protocol for low contamination risk of autologous serum drops in the management of ocular surface disorders. Br J Ophthalmol. 2004;88:464-465.
9. Tsubota K, Goto E, Fujita H, et al. Treatment of dry eye by autologous serum application in Sjogren's syndrome. Br J Ophthalmol. 1999;83:390- 395.
10. Simoni J, Simoni G, Garcia EL, et al. Protective effect of selenium on hemoglobin mediated lipid peroxidation in vivo. Artif Cells Blood Substit Immobil Biotechnol. 1995;23:469-486.
11. Crosby WH, Furth FW. A modification of the benzidine method for measurement of hemoglobin in plasma and urine. Blood. 1956;11:380- 383.
12. Yoon KC, Heo H, Im SK, et al. Comparison of autologous serum and umbilical cord serum eye drops for dry eye syndrome. Am J Ophthalmol. 2007;144:86-92.
13. Holzer MP, Auffarth GU, Specht H, et al. Combination of transepithelial phototherapeutic keratectomy and autologous serum eyedrops for treatment of recurrent corneal erosions. J Cataract Refract Surg. 2005; 31:1603-1606.
14. Brown SM, Lamberts DW, Reid TW, et al. Neurotrophic and anhidrotic keratopathy treated with substance P and insulinlike growth factor 1. Arch Ophthalmol. 1997;115:926-927.